Q-omics provides the consensus-scored SHANK2 profile across patient tissues and cancer cell-line models. SHANK2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SHANK2 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, SHANK2 RNA expression shows 18,818 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight HNSC, THCA, and KIRP as cancer lineages where SHANK2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SHANK2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SHANK2 survival associations across molecular data types. SHANK2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (10) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SHANK2 RNA expression–survival associations across cancer types. High SHANK2 expression shows unfavorable associations in HNSC, CESC and PAAD, but favorable associations in BRCA, LGG and KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SHANK2 RNA expression.
This table summarizes SHANK2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SHANK2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SHANK2 shows lower tumor expression in THCA, LUSC, LUAD, KIRP and KIRC and higher tumor expression in LIHC. The THCA box plot shows higher SHANK2 RNA expression in normal versus tumor tissue (log2 FC = −2.580, t-test p < 0.001).
This table shows molecular features associated with SHANK2 in patient tissues and cancer cell lines. In patient samples, SHANK2 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, SHANK2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and OVARY.
